Table 1

Model inputs

Parameter	Base case	Lower limit	Higher limit	Distribution	Parameter 1	Parameter 2	Reference
SVR rates
SOF/VEL, NC	0.984	0.960	0.996	Uniform	0.960	0.996	18
SOF/VEL, C	0.958	0.789	0.999	Uniform	0.789	0.999	18
EBR/GZR, NC	0.980	0.937	1	Uniform	0.937	1	19
EBR/GZR, C	1	0.937	1	Uniform	0.937	1	19
3D, NC	0.993	0.976	1	Uniform	0.976	1	20
3D, C	0.942	0.892	0.991	Uniform	0.892	0.991	21
DCV/ASV, NC	0.889	0.85	0.94	Uniform	0.85	0.94	22
DCV/ASV, C	0.911	0.85	0.94	Uniform	0.85	0.94	22
SD, NC	0.98	0.95	1	Uniform	0.95	1	23
SD, C	0.98	0.95	1	Uniform	0.95	1	23
SR, NC	0.94	0.87	0.99	Uniform	0.87	0.99	24
SR, C	0.94	0.87	0.99	Uniform	0.87	0.99	24
Annual transition probabilities
Fibrosis progression
F0–F1	0.117	0.104	0.130	Beta	274.98	2075.30	25
F1–F2	0.085	0.075	0.096	Beta	210.06	2261.18	25
F2–F3	0.120	0.109	0.133	Beta	288.05	2112.38	25
F3–F4	0.116	0.104	0.129	Beta	270.61	2062.22	25
Cirrhosis progression
F4-DC	0.039	0.010	0.079	Beta	3.51	86.48	26
F4-HCC	0.014	0.010	0.079	Beta	0.18	12.38	26
F4-SVR to DC	0.003	0.002	0.004	Beta	96	31 821	27
F4-SVR to DC	0.006	0.005	0.007	Beta	95	15 814	27
Liver disease progression
DC-HCC	0.068	0.054	0.082	Beta	89	1226	28
Receiving liver transplant
DC-LT	0.0003	0.0002	0.0011	Beta	0	0.1	29
HCC-LT	0.0005	0.0	0.0024	Beta	4.1	8788.8	29
Mortality rates
DC-death	0.129	0.1032	0.5124	Beta	147.03	983.97	28
HCC-death	0.427	0.3416	0.5124	Beta	117.1	155.23	28
LT-death	0.116	0.060	0.420	Beta	1.3	9.9	30
PLT-death	0.044	0.060	0.420	Beta	4.7	101.6	30
Drug costs							Local charge
SOF/VEL	10 087	7565	12 608
EBR/GZR	8548	6411	10 685
3D	8546	6409	10 682
DCV/ASV	8378	6283	10 472
SD	12 302	9226	15 377
SR	17 096	12 822	21 370
Annual health state costs
F0–F3	992	671	1313	Gamma	6002	0.165	31
F4	2823	1001	4646	Gamma	8570	0.329	31
DC	6287	3820	8755	Gamma	31 403	0.200	31
HCC	13 272	9544	17 000	Gamma	92 610	0.143	31
LT (first year)	56 719	40 983	81 956	Gamma	308 255	0.184	32
LT (subsequent years)	9016	8196	10 077	Gamma	170 113	0.053	32
Utilities
F0–F3	0.790	0.632	0.948	Beta	19.4	5.2	33 35
F4	0.748	0.598	0.898	Beta	23.5	7.9	33 35
DC	0.672	0.538	0.806	Beta	30.8	15.0	33 35
HCC	0.610	0.488	0.732	Beta	36.8	23.6	33 35
LT (first year)	0.560	0.520	0.780	Beta	33.0	17.8	33 35
LT (subsequent years)	0.709	0.567	0.851	Beta	27.2	11.2	33 35
Post SVR	0.87	0.65	1	Uniform	0.65	1	34

ASV, asunaprevir; C, cirrhotic; 3D, ombitasvir/paritaprevir/ritonavir+dasabuvir; DC, decompensated cirrhosis; DCV, daclatasvir; EBR, elbasvir; F0–F4, METAVIR liver fibrosis scores, F0 (no fibrosis), F1 (portal fibrosis with no septa), F2 (portal fibrosis with few septa), F3 (numerous septa without cirrhosis), and F4 (compensated cirrhosis); GZR, grazoprevir; HCC, hepatocellular carcinoma; LT, liver transplant; NC, non-cirrhotic; PLT, post liver transplant; SD, sofosbuvir+daclatasvir; SOF, sofosbuvir; SR, sofosbuvir+ribavirin; SVR, sustained virologic response; VEL, velpatasvir.